The first quarter of 2025 has witnessed a flurry of biotech partnerships and acquisitions, with pharmaceutical giants and emerging biotechs alike forging strategic alliances to accelerate drug development across multiple therapeutic areas. From small molecules to T-cell engagers and RNA medicines, the deal landscape reflects the industry's continued focus on innovation and collaboration.
February Deal Highlights: Acquisitions and Strategic Partnerships
Swiss pharmaceutical giant Novartis made headlines in February with its acquisition of Massachusetts-based Anthos Therapeutics in a deal worth up to $2.15 billion, including $925 million upfront. The acquisition gives Novartis control of Anthos's monoclonal antibody program targeting stroke prevention and systemic embolism.
Eli Lilly continued its strategic expansion by acquiring California-based Organovo's FXR program, including an inflammatory bowel disease drug candidate poised to enter Phase 2 trials. Financial terms remained undisclosed, but the move aligns with Lilly's growing portfolio in immunology.
In a significant merger, American biotechs Alumis and Acelyrin announced plans to combine forces, creating a specialized entity focused on immune-mediated diseases with a combined cash runway of $737 million. Alumis stockholders will own 55% of the new company, with Acelyrin holding the remaining 45%.
Small Molecules Generate Significant Interest
Small molecule therapeutics dominated February's licensing landscape. Japanese multinational Takeda partnered with American biotech BridGene Biosciences in a $46 million deal focused on neurology and immunology drug targets, with potential milestone payments reaching $770 million.
U.S.-based Genesis Therapeutics and Incyte signed a $30 million licensing agreement leveraging Genesis's artificial intelligence platform to discover small molecules for undisclosed targets, with milestone payments potentially reaching $295 million.
In the oncology space, Immuneering and Regeneron formed a partnership to develop IMM-1-104, a small molecule cyclic inhibitor, in combination with Regeneron's monoclonal antibody Libtayo for advanced non-small cell lung cancer.
Monoclonal Antibodies and RNA Medicines
Chinese biotech Bio-Thera Solutions and Indian firm Intas Pharmaceuticals established a partnership for BAT2506, a biosimilar of the monoclonal antibody golimumab targeting TNF-α. The deal includes $21 million upfront and up to $143.5 million in milestone payments.
In the RNA therapeutics space, Merck collaborated with Canadian biotech Epitopea to identify tumor-specific antigens in solid tumors, in a deal worth up to $300 million in milestones. Eli Lilly partnered with South Korean biotech OliX to develop antisense oligonucleotide OLX75016 for metabolic dysfunction-associated steatohepatitis (MASH).
Biogen established ties with Massachusetts-based Stoke Therapeutics, providing $165 million upfront for zorevunersen, an antisense oligonucleotide in clinical trials for Dravet syndrome, with potential milestone payments of up to $385 million.
Emerging Technologies Attract Major Players
T-cell engagers continued to generate significant interest, with AbbVie partnering with Massachusetts-based Xilio Therapeutics to develop masked T-cell engagers designed to activate only within tumor microenvironments. Xilio received $52 million upfront with potential milestone payments of up to $2.1 billion.
German pharmaceutical company Boehringer Ingelheim collaborated with British biotech ExpressionEdits to leverage its AI-powered Genetic Syntax Engine for gene therapy development, while Eli Lilly continued its partnership spree with a $40 million deal with American biotech Magnet Biomedicine focused on molecular glue degraders.
March Deal Landscape: Obesity Therapeutics and Protein Therapies Take Center Stage
March 2025 saw AstraZeneca and Novo Nordisk emerge as top collaborators, with a notable increase in mergers and acquisitions compared to February.
Major Acquisitions Reshape the Landscape
AstraZeneca made a significant move with its billion-dollar acquisition of Belgian biotech EsoBiotec and its Engineered NanoBody Lentiviral (ENaBL) platform, which programs immune cells to target cancer and potentially autoimmune diseases.
Bristol Myers Squibb initiated a tender offer to acquire all outstanding shares of 2seventy bio at $5.00 per share, representing a $286 million all-cash transaction. The companies have previously collaborated on Abecma, an FDA-approved CAR-T cell therapy for multiple myeloma.
French pharmaceutical company Sanofi acquired California-based Dren Bio's bispecific myeloid cell engager DR-0201 for $600 million upfront, with potential milestone payments of up to $1.3 billion. The clinical candidate targets specific myeloid cells to induce B-cell depletion via targeted phagocytosis.
Obesity Therapeutics Gain Momentum
One of the most notable trends in March was the increased focus on obesity therapeutics. AbbVie entered the field through a partnership with Danish biotech Gubra for GUB014295, a long-acting amylin analog. The deal includes $350 million upfront and potential milestone payments of up to $1.875 billion.
Roche and Danish peptide company Zealand Pharma signed a licensing agreement for petrelintide, an amylin analog obesity drug. Zealand will receive $1.65 billion upfront and can earn up to $3.6 billion in development and sales-based milestones.
Novo Nordisk continued its strategic expansion in metabolic disorders by partnering with American biotech Lexicon to develop LX9851, an oral non-incretin drug candidate for obesity. The deal includes payments of up to $1 billion for exclusive worldwide rights.
Protein Therapies and Small Molecules
AstraZeneca formed multiple partnerships in March, including a collaboration with China-based Syneron Bio to develop macrocyclic peptides for chronic diseases. Syneron will receive $75 million in upfront and near-term payments, with potential milestone payments of up to $3.4 billion.
The British pharmaceutical giant also partnered with South Korean company Alteogen to develop ALT-B4, a hyaluronidase utilizing Hybrozyme platform technology that enables subcutaneous administration of drugs typically given intravenously.
Novo Nordisk and Massachusetts-based startup Gensaic established a partnership leveraging Gensaic's AI-enabled protein design technology to develop drug candidates for heart and metabolic diseases, with potential payments of up to $354 million.
Bispecific Antibodies and RNA Medicines
AstraZeneca collaborated with Chinese biotech Harbour BioMed to gain access to its Harbour Mice fully human antibody technology platform, paying $175 million in upfront and near-term payments with potential milestone payments of up to $4.4 billion.
In the RNA therapeutics space, Japanese company Ono Pharmaceutical partnered with California-based Ionis Pharmaceuticals, providing $280 million upfront for sapablursen, an antisense oligonucleotide targeting RNA for the treatment of polycythemia vera.
Industry Implications and Future Outlook
The first quarter of 2025 has demonstrated the biopharmaceutical industry's continued commitment to innovation through strategic partnerships and acquisitions. Several key trends have emerged:
-
Obesity therapeutics have gained significant momentum, with major pharmaceutical companies making substantial investments in novel approaches, particularly amylin analogs and GLP-1 receptor agonists.
-
RNA therapeutics continue to attract significant investment, reflecting the growing confidence in this modality for addressing previously undruggable targets.
-
AI-enabled drug discovery platforms are increasingly being integrated into traditional pharmaceutical R&D processes, as evidenced by partnerships between established pharmaceutical companies and AI-focused biotechs.
-
T-cell engagers and other immunotherapeutic approaches remain a priority, particularly in oncology, with companies exploring novel mechanisms to enhance efficacy while minimizing off-target effects.
As we move further into 2025, these partnerships are expected to accelerate the development of innovative therapies across multiple disease areas, potentially bringing new treatment options to patients with significant unmet medical needs.
